Valeant Board Tells CEO To Cooperate With Senators
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International Inc.'s board on April 11 took an unusual move in declaring it had asked the company's soon-to-be-exiting CEO Michael Pearson to cooperate with the US Senate Committee on Aging's subpoena for a deposition.
You may also be interested in...
Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?
Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.